Screener
Summit Therapeutics SMMT Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: Summit Therapeutics’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 5:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001599298-26-000039
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Non-current liabilities: | ||
| Operating lease liabilities, net of current portion | 16,859 | 17,502 |
| Other non-current liabilities | 1,799 | 1,832 |
| Total liabilities | 101,924 | 92,322 |
| Commitments and contingencies (Note 12) | ||
| Stockholders' equity: | ||
| Preferred stock, $0.01 par value, 20,000,000 shares authorized; none issued and outstanding at March 31, 2026 and December 31, 2025, respectively | — | — |
| Common stock, $0.01 par value: 1,000,000,000 shares authorized; 776,017,474 and 775,371,200 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 7,760 | 7,754 |
Item 1. Financial Statements.
FAQ
- What is Summit Therapeutics's total liabilities?
- Summit Therapeutics (SMMT) reported total liabilities of $101.92M in Q1 2026.
- How has Summit Therapeutics's total liabilities changed year-over-year?
- Summit Therapeutics's total liabilities increased by 158.1% year-over-year, from $39.49M to $101.92M.
- What is the long-term trend for Summit Therapeutics's total liabilities?
- Over 5 years (2020 to 2025), Summit Therapeutics's total liabilities has grown at a 32.0% compound annual growth rate (CAGR), from $23.05M to $92.32M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about Summit Therapeutics's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude